Nuvation Bio Inc.
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
NUVB$4.35+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following exhibits are filed as part of this report:
| ExhibitNumber | Description |
| 3.1 | Amended and Restated Certificate of Incorporation previously filed with the SEC on February 12, 2021 as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39351), which is incorporated herein by reference. |
| 3.2 | Amended and Restated Bylaws previously filed with the SEC on February 12, 2021 as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-39351), which is incorporated herein by reference. |
| 10.1#*† | Nuvation Bio Inc. 2021 Equity Incentive Plan, as amended. |
| 10.2#† | Forms of Option Grant Notice and Option Agreement under the 2021 Equity Incentive Plan – Long-Term Incentive Program previously filed with the SEC on May 9, 2022 as Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39351), which is incorporated herein by reference. |
| 10.3*‡ | Contract Manufacturing Agreement (API) between Registrant and Asymchem Laboratories (Tianjin) Co., Ltd., dated March 3, 2025. |
| 10.4*‡ | Contract Manufacturing Agreement (Drug Product) between Registrant and Asymchem Life Science (Tianjin) Co., Ltd., dated March 21, 2025. |
| 10.5 | Senior Secured Loan Agreement between Registrant and Sagard Holdings Manager LP, previously filed with the SEC on March 6, 2025 as Exhibit 10.23 to the Registrant's Annual Report on Form 10-K (File No. 001-39351), which is incorporated herein by reference. |
| 10.6 | Revenue Interest Financing Agreement between Registrant and Sagard Healthcare Partners (Delaware) II LP, previously filed with the SEC on March 6, 2025 as Exhibit 10.24 to the Registrant's Annual Report on Form 10-K (File No. 001-39351), which is incorporated herein by reference. |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |
| 104 | Cover page formatted as inline XBRL and contained in Exhibit 101 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.